Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307339 | 0.95 | HPGD (0.47) | HPGDALDH1A1MAPK1NAMPTF2 | |
| SCHEMBL1308069 | 0.93 | HPGD (0.42) | HPGDALDH1A1MAPK1NAMPTF2 | |
| SCHEMBL12034937 | 0.93 | HPGD (0.42) | HPGDALDH1A1MAPK1NAMPTF2 | |
| SCHEMBL1306300 | 0.92 | MAPK1 (0.48) | HPGDALDH1A1MAPK1TSHRMEN1 | |
| SCHEMBL1306667 | 0.91 | HPGD (0.42) | HPGDALDH1A1MAPK1NAMPTF2 | |
| SCHEMBL3812592 | 0.86 | HSD17B10 (0.46) | HPGDALDH1A1MAPK1NAMPTF2 | |
| SCHEMBL12117301 | 0.85 | HPGD (0.45) | HPGDALDH1A1MAPK1NAMPTMEN1 | |
| SCHEMBL1308010 | 0.81 | HPGD (0.46) | HPGDALDH1A1NAMPTF2MEN1 | |
| SCHEMBL12034882 | 0.81 | HPGD (0.44) | HPGDALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL3818854 | 0.80 | HPGD (0.46) | HPGDALDH1A1MAPK1NAMPTF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, CYP11B1, HSD11B2 | HPGD 27/4885ALDH1A1 187/4885MAPK1 1496/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | HPGD 28/4885ALDH1A1 206/4885MAPK1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.